Evaxion Refocuses on Cancer Vaccines as Q3 Loss Narrows to $3.5M, Cash Runway to Late 2027
EVAX sits 16% above its 52-week low of $2.425.
Summary
Evaxion is narrowing its pipeline to immuno-oncology, prioritizing off-the-shelf cancer vaccines EVX-04 and EVX-05 and pushing EVX-01 into more indications through partnerships. Infectious disease and autoimmune work will only continue with external partner funding, and the company said it will make organizational adjustments as a result. Q3 2026 net loss was $3.5 million, or a loss of 1 cent per share, versus a $3.7 million loss in Q2 and a $4.6 million profit a year ago, when revenue came from out-licensing EVX-B3 to MSD; no revenue was booked this quarter. Cash stood at $13.3 million at September 30, down from $14.0 million at June 30, with the runway extended toward the end of 2027 after $2.2 million in gross ATM proceeds. The near-term milestone is the EVX-04 phase 1 trial application, targeted before year-end, with target validation data due at ASH December 12-15.
Updates
· SEC 6-K — Evaxion's Q3 2026 R&D expenses were $2.3 million and G&A $1.4 million; total equity fell to $8.1 million from $17.0 million at December 31, 2025.
At the time of this announcement, EVAX was trading at $2.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.2M. The 52-week trading range was $2.43 to $6.92. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.